A meta-analysis pooling 13 observational studies demonstrated that plasma visfatin concentration was increased in participants diagnosed with overweight/obesity, type 2 diabetes mellitus, metabolic syndrome, or cardiovascular disease. Here, NAMPT is linked to obesity disorder.